Head of the Class: An Interview with MIT's Robert Langer
Executive SummaryPerhaps no single person represents the biomedical industry's past three decades of evolution better than MIT professor Bob Langer. He's counted as the founder of more than two dozen companies, reflecting a commitment to both making new discoveries and getting them into the hands of people who can benefit from them.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.